High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis

Oncotarget

Volumn 6, Issue 9, 2015, Pages 6850-6861

  Huang, Zhi Liang ^a   Lin, Zhi Rui ^a   Xiao, Yi Ren ^b   Cao, Xun ^a   Zhu, Lin Chun ^a   Zeng, Mu Sheng ^a   Zhong, Qian ^a   Wen, Zhe Sheng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

Esophageal squamous carcinoma (ESCC); Immunohistochemistry; Prognostic biomarker; TACC3

Indexed keywords

MESSENGER RNA; TRANSFORMING ACIDIC COILED COIL PROTEIN 3; TUMOR MARKER; UNCLASSIFIED DRUG; FETOPROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TACC1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TACC3 GENE; UPREGULATION; WESTERN BLOTTING; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL MOTION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL NEOPLASMS; FEMALE; FETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PROGNOSIS; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84927145209     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3190     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 200. GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010; 127:2893-2917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, Mark SD, Qiao YL, Taylor PR. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. International journal of cancer Journal international du cancer. 2005; 113:456-463.
4. Montesano R, Hollstein M, Hainaut P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. International journal of cancer Journal international du cancer. 1996; 69:225-235.
5. Gergely F, Kidd D, Jeffers K, Wakefield JG, Raff JW. D-TACC: a novel centrosomal protein required for normal spindle function in the early Drosophila embryo. The EMBO journal. 2000; 19:241-252.
6. Gergely F, Karlsson C, Still I, Cowell J, Kilmartin J, Raff JW. The TACC domain identifies a family of centrosomal proteins that can interact with microtubules. Proc Natl Acad Sci U S A. 2000; 97:14352-14357.
7. Lappin TR, Mullan RN, Stewart JP, Morgan NA, Thompson A, Maxwell AP. AINT/ERIC/TACC: an expand{reversed not sign}ing family of proteins with C-terminal coiled coil domains. Leuk Lymphoma. 2002; 43:1455-1459.
8. Giet R, McLean D, Descamps S, Lee MJ, Raff JW, Prigent C, Glover DM. Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. The Journal of cell biology. 2002; 156:437-451.
9. Still IH, Vince P, Cowell JK. The third member of the trans{reversed not sign}forming acidic coiled coil-containing gene family, TACC3, maps in 4p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics. 1999; 58:165-170.
10. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, Sato Y, Okuno Y. Genomic and molecular characterization of esophageal squamous cell carcinoma Nature genetics. 2014; 46:467-473.
11. Kinoshita K, Noetzel TL, Pelletier L, Mechtler K, Drechsel DN, Schwager A, Lee M, Raff JW, Hyman AA. Aurora A phosphorylation of TACC3/maskin is required for centrosome-dependent microtubule assembly in mitosis. J Cell Biol. 2005; 170:1047-1055.
12. Lioutas A, Vernos I. Aurora A kinase and its substrate TACC3 are required for central spindle assembly. EMBO Rep. 2013; 14:829-836.
13. Schmidt S, Schneider L, Essmann F, Cirstea IC, Kuck F, Kletke A, Janicke RU, Wiek C, Hanenberg H, Ahmadian MR, Schulze-Osthoff K, Nurnberg B, Piekorz RP. The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program. Oncogene. 2010; 29:6184-6192.
14. Schneider L, Essmann F, Kletke A, Rio P, Hanenberg H, Schulze-Osthoff K, Nurnberg B, Piekorz RP. TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest. Oncogene. 2008; 27:116-125.
15. Sadek CM, Pelto-Huikko M, Tujague M, Steffensen KR, Wennerholm M, Gustafsson JA. TACC3 expression is tightly regulated during early differentiation. Gene Expr Patterns. 2003; 3:203-211.
16. Piekorz RP, Hoffmeyer A, Duntsch CD, McKay C, Nakajima H, Sexl V, Snyder L, Rehg J, Ihle JN. The cen{reversed not sign}trosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J. 2002; 21:653-664.
17. Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 2013; 332:63-73.
18. Ha GH, Kim JL, Breuer EK. TACC3 is essential for EGF-mediated EMT in cervical cancer. PloS One. 2013; 8:e70353.
19. Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TR, Shaughnessy J Jr. Correlation of TACC3 FGFR3 MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol. 2004; 126:72-76.
20. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, et al. Integrative and compara{reversed not sign}tive genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014; 32:121-128.
21. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, Gudbjartsson DF, Stacey SN, Gudmundsson J, Zanon C, Kostic J, MassonG, BjarnasonH, Palsson ST, Skarphedinsson OB, Gudjonsson SA, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nature genetics. 2010; 42:415-419.
22. Wang M, Chu H, Yan F, Qin C, Li P, Yuan L, Yin C, Xu J, Zhang Z. Chromosome 4p16.3 variant modify bladder cancer risk in a Chinese population. Carcinogenesis. 2011; 32:872-875.
23. Conte N, Delaval B, Ginestier C, Ferrand A, Isnardon D, Larroque C, Prigent C, Seraphin B, Jacquemier J, Birnbaum D. TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene. 2003; 22:8102-8116.
24. Ulisse S, Baldini E, Toller M, Delcros JG, Gueho A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D'Armiento M, Arlot-Bonnemains Y. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer. 2007; 14:827-837.
25. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012; 337:1231-1235.
26. Wang Y, Shang Y. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Experimental cell research. 2013; 319:160-169.
27. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stemcell traits. Nature reviews Cancer. 2009; 9:265-273.
28. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998; 339:1979-1984.
29. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002; 347:1662-1669.
30. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, WijnhovenBP, RichelDJ, Nieuwenhuijzen GA, HospersGA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, et al. Preoperative chemoradio{reversed not sign}therapy for esophageal or junctional cancer. N Engl J Med. 2012; 366:2074-2084.
31. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013; 381:400-412.
32. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiol{reversed not sign}ogy and end results areas. international du cancer. 2003; 105:98-100.
33. Raff JW. Centrosomes and cancer: lessons from a TACC. Trends Cell Biol. 2002; 12:222-225.
34. Ha GH, Kim JL, Breuer EK. Transforming acidic coiled-coil proteins (TACCs) in human cancer. Cancer Lett. 2013; 336:24-33.
35. Peters DG, Kudla DM, Deloia JA, Chu TJ, Fairfull L, Edwards RP, Ferrell RE. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epi{reversed not sign}thelium by serial analysis of gene expression. Cancer Epidemiol Biomarkers Prev. 2005; 14:1717-1723.
36. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD, Still IH. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health. 2005; 5:8.
37. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemora{reversed not sign}diotherapy or chemotherapy in oesophageal carcinoma:a meta-analysis. The Lancet Oncology. 2007; 8:226-234.
38. Yao R, Natsume Y, Saiki Y, Shioya H, Takeuchi K, Yamori T, Toki H, Aoki I, Saga T, Noda T. Disruption of Tacc3 function leads to in vivo tumor regression. Oncogene. 2012; 31:135-148.
39. Ha GH, Kim JL, Petersson A, Oh S, Denning MF. TACC3 deregulates the DNA damage response and confers sensi{reversed not sign}tivity to radiation and PARP inhibition Oncogene. 2014; 0. doi:10.1038/onc.2014.105. [Epub ahead of print].
40. Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q, Zeng MS. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer biology & therapy. 2014; 15:1613-1621.
41. Yao R, Kondoh Y, Natsume Y, Yamanaka H, Inoue M, Toki H, Takagi R, Shimizu T, Yamori T, Osada H, Noda T. A small compound targeting TACC3 revealed its different spatiotemporal contributions for spindle assembly in cancer cells. Oncogene. 2014; 33:4242-4252.
42. Ohoka N, Nagai K, Hattori T, Okuhira K, Shibata N, Cho N, Naito M. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway. Cell death & disease. 2014; 5:e1513.
43. Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 2010; 1:265-277.
44. Sobin LH GM, Wittekind C. TNM classification of malig{reversed not sign}nant tumors. 7th edition. (New Jersey: Wiley-Blackwell). 46:15-19.
45. Liu WL, Guo XZ, Zhang LJ, Wang JY, Zhang G, Guan S, Chen YM, Kong QL, Xu LH, Li MZ, Song LB, Zeng MS. Prognostic relevance of Bmi-1 expression and autoantibod{reversed not sign}ies in esophageal squamous cell carcinoma. BMC Cancer. 2010; 10:467.
46. Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, Fu L, Zhang N, Tong AH, Qin YR, Tsao SW, Chan KW, Lok S, Guan XY. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell car{reversed not sign}cinom. Gastroenterology. 675-686. 2012; 143:675-686.e671-612.